Taizhou Medical Hi-Tech Zone (also called as China Medical City (CMC)), located in Taizhou, an important part of the Yangtze River Delta region, is China’s first national medical high-tech zone established by the Ministry of Science and Technology, National Health and Family Planning Commission, China Food and Drug Administration, State Administration of Traditional Chinese Medicine and the People’s Government of Jiangsu Province, covering a planned area of 30 square kilometers and consisting of functional zones such as the R&D zone, production and manufacturing zone, exhibition and trading zone, healthy care zone, education zone and comprehensive supporting zone.
Since the start of its construction, CMC has committed to building China’s largest biomedical industry base with the most complete industry chain according to the construction concept of “revitalizing the city with the industry, promoting the industry with the city, integrating the city with the industry and achieving mutual prosperity of the city and industry”. At present, CMC has gathered over 50 foreign and domestic well-known universities and pharmaceutical R&D institutions such as AstraZeneca, Takeda Pharmaceuticals, Boehringer Ingelheim, CSPC and Neptunus, declared over 400 "world-class, industry-leading" innovative medical results, and attracted over 1,580 foreign and domestic top talents for start-ups, among whom 24 have been included in the Recruitment Program of Global Experts. Moreover, CMC has been listed as a trial district of the national new vaccine and specific diagnostic reagent industry cluster with a starting development area of 10.8 square kilometers.
Products currently in development cover a variety of therapeutic areas including oncology and autoimmune diseases. Our R&D management team has extensive experience in the development and commercialization of a range of monoclonal antibody drugs in such leading international pharmaceutical and biotech companies as Genentech, Amgen, BMS and Eli Lilly. The concept of our drug development lies in global integrative innovation. We also have 3 R&D laboratories located in China (Shanghai), the US (California) and Taiwan (Taipei).
In the six years since its foundation, Henlius has been a leader in antibody drug development in China, completing the IND submissions of 6 product candidates with 10 indications. The most advanced product in our pipeline, the 'Recombinant Murine/Human Chimeric Anti-CD20 Monoclonal Antibody Injection', and the second product HLX02 ‘Recombinant humanized Anti-Her2 Monoclonal Antibody Injection’ have obtained clinical trial approval by the China Food and Drug Administration (CFDA), and HLX01 has entered the Phase III study.
Looking forward, Henlius will continue to pursue innovation in drug discovery and development and strive to bring effective, safe and affordable drugs to millions of people in need in China and beyond.